Professional development

Open innovation is more than just the latest pharma industry buzzword. Done right, it can help overcome funding challenges and accelerate discovery across the board.

In today’s highly competitive academic world, are we losing sight of the real goal of biomedical research in our rush to secure funding and embrace the latest technologies?

Making grant application processes tougher can have an unexpected and dramatic effect on the demographics of applicants. Let’s not force young investigators to fall at the first hurdle.

Robert Coffin tells the bench-to-bedside story of how the first FDA-approved oncolytic virotherapy, talimogene laherparepvec (T-VEC), was translated from a colleague’s cold sore to a potential global game changer.

Sitting Down With… Jennifer Grandis, Professor, Department of Otolaryngology – Head and Neck Surgery, Associate Vice Chancellor – Clinical and Translational Research, University of California, San Francisco, USA.

In the pharma industry of the future, only the strongest companies will survive – and that means those with the most successful collaborations.

Telling stories from across the translational spectrum